Jasper Therapeutics Inc Stock Price, News & Analysis

Jasper Therapeutics (JSPR) reported positive preliminary data from its BEACON Phase 1b/2a study of briquilimab in treating Chronic Spontaneous Urticaria (CSU). The study showed significant clinical responses across multiple dosing cohorts, with the 240mg single-dose group achieving a mean UAS7 change of -26.6 from baseline at 8 weeks.

Key highlights include 100% Complete Response (UAS7 = 0) in the 240mg single-dose cohort (N=3) at 8 weeks, with 66% maintaining Well Controlled disease at 12 weeks. Multiple dosing regimens ≥120mg demonstrated UAS7 changes exceeding -25 points. The drug showed rapid onset of action, with responses observed as early as 1-week post-first dose.

Briquilimab demonstrated a favorable safety profile with no dose-limiting toxicities. Based on these results, Jasper plans to commence a CSU registrational program with a Phase 2b study in the second half of 2025.

Jasper Therapeutics (Nasdaq: JSPR), a clinical-stage biotechnology company, will host a webinar on January 8, 2025, at 8am EST to present preliminary data from the BEACON study of briquilimab in Chronic Spontaneous Urticaria (CSU). This virtual event will feature remarks from Thomas B. Casale, M.D., Professor of Medicine and Pediatrics at the University of South Florida Morsani College of Medicine, who is the lead US investigator in the BEACON study. Briquilimab is a novel antibody therapy targeting c-Kit (CD117) and aims to address mast cell-driven diseases such as CSU, chronic inducible urticaria (CIndU), and asthma.

For those interested in attending, the registration details are as follows:

• Date: Wednesday, January 8, 2025
• Time: 8:00am EST
• Registration: Click Here

Jasper Therapeutics (Nasdaq: JSPR) has announced the first patient dosing in its Phase 1b/2a ETESIAN clinical study evaluating briquilimab in allergic asthma. The study will test a single 180mg subcutaneous dose of briquilimab in approximately 30 patients across up to 7 sites in Canada. This marks Jasper's third clinical program for briquilimab in inflammatory diseases driven by mast cell activity. The double-blind, placebo-controlled challenge study aims to demonstrate proof-of-concept in asthma, with initial data expected in the second half of 2025. Key assessments will include early and late asthmatic response, airway hyperresponsiveness, and mast cell depletion and recovery.

Jasper Therapeutics (Nasdaq: JSPR), a clinical stage biotech company developing briquilimab, announces its participation in three upcoming investor conferences. The company will present at the Stifel 2024 Healthcare Conference (Nov 18-19) with a fireside chat on Nov 18 at 9:45 AM ET, the Jefferies London Healthcare Conference (Nov 19-21), and the 7th Annual Evercore ISI HealthCONx Conference (Dec 3-5) with a fireside chat on Dec 3 at 3:25 PM ET. Briquilimab is a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.

Jasper Therapeutics (JSPR) reported Q3 2024 financial results and provided updates on its briquilimab development programs. The company reported positive preliminary data from the SPOTLIGHT study in CIndU, with 93% of participants in the 40mg and 120mg dose cohorts achieving clinical response. Financial highlights include cash position of $92.5 million, R&D expenses of $14.5 million, and a net loss of $18.6 million ($1.24 per share). The company discontinued its LR-MDS program but advanced its chronic urticaria and asthma studies, with initial BEACON study data expected in January 2025.

Jasper Therapeutics (Nasdaq: JSPR) will present preclinical data for briquilimab, their novel antibody therapy targeting c-Kit (CD117), at the ACAAI Annual Scientific Meeting in Boston from October 24-28, 2024. The therapy aims to treat mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.

Three presentations will showcase promising preclinical results demonstrating briquilimab's effectiveness in mast cell depletion and its ability to bind c-Kit with high potency. The studies include both in-vitro data and non-human primate research, supporting the drug's pharmacodynamics. All presentations will take place on Friday, October 25, 2024, in Exhibit Hall A.

Jasper Therapeutics (JSPR) announced an expansion of its clinical program for chronic urticaria treatments. The company is initiating an open-label extension study that will include patients from both BEACON and SPOTLIGHT studies. Additionally, Jasper received regulatory approval in the US and EU to add a 360mg single-dose cohort to the BEACON study in chronic spontaneous urticaria (CSU), with enrollment already begun.

Initial data from all doses up to 240mg in the BEACON study will be reported during the week of January 6th, 2025, while data from the new 360mg cohort is expected in the first half of 2025. The company plans to commence registrational studies in the second half of 2025.

Jasper Therapeutics (Nasdaq: JSPR) reported positive data from its SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adults with chronic inducible urticaria (CIndU). Key findings include:

- 14 of 15 participants (93%) achieved a clinical response within 6 weeks
- In the 120mg dose cohort, 10 of 12 participants (83%) experienced a complete response
- No serious adverse events or grade 3+ adverse events reported
- Significant reductions in tryptase observed, correlating with clinical responses

The company plans to enroll a 180mg dose cohort and expects to present full data in the first half of 2025. Additionally, Jasper anticipates reporting initial data from all cohorts of the BEACON study in chronic spontaneous urticaria during the week of January 6th, 2025.

Jasper Therapeutics (Nasdaq: JSPR) announced Health Canada's clearance of its Clinical Trial Application for a Phase 1b/2a asthma challenge study evaluating briquilimab. The study, set to enroll 30 patients across Canada and the EU, aims to demonstrate proof-of-concept for mast cell depletion as an effective mechanism in asthma treatment. Key assessments include early and late asthmatic response, airway hyperresponsiveness changes, and mast cell depletion.

The company plans to begin dosing patients in Q4 2024 and report initial data in H2 2025. Additionally, Jasper received trademark approval for its proprietary Jasper c-Kit Mouse™ model, which enables direct testing of c-Kit inhibitors across various diseases, overcoming limitations of standard models.